JVI </> Advertise
<http://ad.doubleclick.net/click;h=v8/3648/0/0/%2a/y;25383424;0-0;0;11664085;767-220/40;14139887/14157783/1;;~aopt=2/1/1d/0;~sscs=%3fhttp://estore.asm.org/browse/index.asp?plid=3&categoryid=50>

Home </> Help </help/> [Feedback] </cgi/feedback> [For Subscribers]
</subscriptions/> [Archive] </contents-by-date.0.shtml> [Search]
</search.dtl> [Contents] </content/vol82/issue1/index.dtl>
*Institution: University of Pittsburgh HSLS* Sign In as Member
</cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F82%2F1%2F1>
------------------------------------------------------------------------
This Article
Right arrow	* *Full Text* (PDF) </cgi/reprint/82/1/1> *
Right arrow	* Alert me when this article is cited
</cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jvi;82/1/1&return_type=article&return_url=http%3A%2F%2Fjvi.asm.org%2Fcgi%2Fcontent%2Ffull%2F82%2F1%2F1>*

Right arrow	* Alert me if a correction is posted
</cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=82/1/1&return_type=article&return_url=http%3A%2F%2Fjvi.asm.org%2Fcgi%2Fcontent%2Ffull%2F82%2F1%2F1>*

Services
Right arrow	* Similar articles in this journal
</cgi/search?qbe=jvi;82/1/1&journalcode=jvi&minscore=4000> *
Right arrow	* Alert me to new issues of the journal
<http://journals.asm.org/cgi/alerts/etoc>*
Right arrow	* Download to citation manager </cgi/citmgr?gca=jvi;82/1/1>*
Right arrow	**Copyright Information
<http://www.journals.asm.org/misc/terms.shtml>**
Right arrow	**Books from ASM Press <http://www.asmpress.org/>**
Right arrow	**MicrobeWorld <http://www.microbeworld.org/>**

Journal of Virology, January 2008, p. 1-19, Vol. 82, No. 1
0022-538X/08/$08.00+0     doi:10.1128/JVI.02322-07
Copyright  2008 </misc/terms.shtml>, American Society for Microbiology
<http://www.asm.org>. All Rights Reserved.

*Instructions to Authors*


    JOURNAL OF VIROLOGY


      2008 INSTRUCTIONS TO AUTHORS

    *SCOPE <#SCOPE>*
    *EDITORIAL POLICY <#EDITORIAL_POLICY>*
    *    Use of Microbiological Information
    <#Use_of_Microbiological_Information>*
    *    General Requirements <#General_Requirements>*
    *    Primary Publication <#Primary_Publication>*
    *    Permissions <#Permissions>*
    *    Authorship <#Authorship>*
    *    Conflict of Interest <#Conflict_of_Interest>*
    *    Copyright <#Copyright>*
    *    Funding Agency Repositories <#Funding_Agency_Repositories>*
    *    Use of Human Subjects or Animals in Research
    <#Use_of_Human_Subjects_or_Animals_in_Research>*
    *    Patient Identification <#Patient_Identification>*
    *    Nucleotide and Amino Acid Sequences
    <#Nucleotide_and_Amino_Acid_Sequences>*
    *    Structural Determinations <#Structural_Determinations>*
    *    Microarray Data <#Microarray_Data>*
    *    Supplemental Material <#Supplemental_Material>*
    *    Compliance <#Compliance>*
    *    Warranties and Exclusions <#Warranties_and_Exclusions>*
    *    Page Charges <#Page_Charges>*
    *    Editorial Style <#Editorial_Style>*
    *    Review Process <#Review_Process>*
    *    Notification of Acceptance <#Notification_of_Acceptance>*
    *    Publish ahead of Print <#Publish_ahead_of_Print>*
    *    Page Proofs <#Page_Proofs>*
    *    Reprints <#Reprints>*
    *    PDF Files <#PDF_Files>*
    *HOW TO SUBMIT MANUSCRIPTS <#HOW_TO_SUBMIT_MANUSCRIPTS>*
    *ORGANIZATION AND FORMAT <#ORGANIZATION_AND_FORMAT>*
    *    Full-Length Papers <#Full-Length_Papers>*
    *        Title, running title, and byline.
    <#Title,_running_title,_and_byline.>*
    *        Study group in byline. <#Study_group_in_byline.>*
    *        Correspondent footnote. <#Correspondent_footnote.>*
    *        Abstract. <#Abstract.>*
    *        Introduction. <#Introduction.>*
    *        Materials and Methods. <#Materials_and_Methods.>*
    *        Results. <#Results.>*
    *        Discussion. <#Discussion.>*
    *        Acknowledgments. <#Acknowledgments.>*
    *        Appendixes. <#Appendixes.>*
    *        References. <#References.>*
    *    Notes <#Notes>*
    *    Minireviews <#Minireviews>*
    *    Guest Commentaries <#Guest_Commentaries>*
    *    Letters to the Editor <#Letters_to_the_Editor>*
    *    Errata <#Errata>*
    *    Authors' Corrections <#Authors'_Corrections>*
    *    Retractions <#Retractions>*
    *ILLUSTRATIONS AND TABLES <#ILLUSTRATIONS_AND_TABLES>*
    *    Image Manipulation <#Image_Manipulation>*
    *    Illustrations <#Illustrations>*
    *        File types and formats. <#File_types_and_formats.>*
    *        Minimum resolution. <#Minimum_resolution.>*
    *        Size. <#Size.>*
    *        Contrast. <#Contrast.>*
    *        Labeling and assembly. <#Labeling_and_assembly.>*
    *        Fonts. <#Fonts.>*
    *        Compression. <#Compression.>*
    *        Color illustrations. <#Color_illustrations.>*
    *    Drawings <#Drawings>*
    *    Presentation of Nucleic Acid Sequences
    <#Presentation_of_Nucleic_Acid_Sequences>*
    *    Figure Legends <#Figure_Legends>*
    *    Tables <#Tables>*
    *    Cover Photographs and Drawings <#Cover_Photographs_and_Drawings>*
    *NOMENCLATURE <#NOMENCLATURE>*
    *    Chemical and Biochemical Nomenclature
    <#Chemical_and_Biochemical_Nomenclature>*
    *    Nomenclature of Mice <#Nomenclature_of_Mice>*
    *    Nomenclature of Viruses <#Nomenclature_of_Viruses>*
    *    Nomenclature of Bacteria <#Nomenclature_of_Bacteria>*
    *    Genetic Nomenclature <#Genetic_Nomenclature>*
    *        Locus tags. <#Locus_tags.>*
    *        ''Mutant'' versus ''mutation.''
    <#''Mutant''_versus_''mutation.''>*
    *        ''Homology'' versus ''similarity.''
    <#''Homology''_versus_''similarity.''>*
    *ABBREVIATIONS AND CONVENTIONS <#ABBREVIATIONS_AND_CONVENTIONS>*
    *    Verb Tense <#Verb_Tense>*
    *    Abbreviations <#Abbreviations>*
    *        General. <#General.>*
    *        Not requiring introduction. <#Not_requiring_introduction.>*
    *    Drugs and Pharmaceutical Agents <#Drugs_and_Pharmaceutical_Agents>*
    *    Reporting Numerical Data <#Reporting_Numerical_Data>*
    *    Isotopically Labeled Compounds <#Isotopically_Labeled_Compounds>*


	   SCOPE

Top
<#top> SCOPE
EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
The /Journal of Virology/ (JVI) is devoted to the timely dissemination^
of significant new knowledge about the viruses of animals, archaea,^
bacteria, fungi, plants, and protozoa. Investigators in all^ areas of
basic virology are invited to submit reports of original^ research.
Original articles should contain experimental observations^ that address
a hypothesis, lead to new concepts, and indicate^ new directions in
research. Computational analyses of viruses^ and viral components that
advance the field are also appropriate.^

JVI specifically encourages reports on virus structure and assembly,^
viral genome replication and regulation of viral gene expression,^ viral
genetic diversity and evolution, virus-cell interactions,^ cellular
responses to viral infection, transformation and oncogenesis,^ gene
delivery, viral pathogenesis and immunity, and vaccines^ and antiviral
agents. Manuscripts contributing new information^ about virus-host
interactions?in particular disease mechanisms,^ immune responses, and
immunopathology?are appropriate^ for JVI. Manuscripts describing the
development, mechanisms^ of action, and preclinical evaluation of new
antiviral vaccines^ and therapeutics also are appropriate for JVI. The
editors seek^ to promote the publication of research that enhances an
understanding^ of the virus-cell and virus-organism interface.^

JVI encourages the submission of manuscripts describing studies^ in
which viruses or viral genetic elements are used as components^ of
vectors for the delivery of therapeutic genes into animals^ and plants.
These original articles should contain experimental^ observations that
lead to new concepts and understanding relevant^ to gene delivery,
regulated expression of therapeutic genes,^ or viral pathogenesis. To
promote publications in this area,^ the editors have established a
section of the journal for articles^ relating to gene delivery.^

JVI considers manuscripts that include microarrays and similar^ parallel
profiling analyses of viral or cellular gene expression.^ However, such
manuscripts will be published only if they provide^ novel insight into
the biology of the virus or the infected^ cell or if they form the basis
for additional experiments that^ provide such insights. It is expected
that the primary data^ from such analyses will be incorporated into the
text or figures^ or will be made available as supplementary material on
the ASM^ website, a publicly accessible laboratory website, or a public^
repository (such as the National Center for Biotechnology Information).^

The journal will not publish purely descriptive studies, such^ as those
that solely provide a new restriction map or nucleotide^ sequence;
identify new immunodominant peptides representing^ T- or B-cell
epitopes; or report the isolation or characterization^ of monoclonal
antibodies, a viral variant, or a new strain or^ type. Such information
or reagents must instead be used in further^ experiments to test an idea
or mechanistic model or to relate^ a clear set of novel conclusions that
derive from the data.^

ASM publishes a number of journals covering various aspects^ of
microbiology. Each journal has a prescribed scope that must^ be
considered in determining where to publish each manuscript.^ The
following guidelines may be of assistance.

   1. JVI will consider^ papers that describe the use of antiviral^
      agents in elucidating^ the basic biological processes of viruses^
      and host cells. Papers^ describing other aspects of antiviral^
      agents and chemotherapy^ will be considered for /Antimicrobial^
      Agents and Chemotherapy/.^
   2. JVI will consider all papers dealing with the biology of
      bacteriophages.^ Studies involving the use of bacteriophages as a
      diagnostic^ typing system will be considered by the /Journal of
      Clinical^ Microbiology/. Those dealing with phages in relation to
      industrial^ microbiology will be considered by /Applied and
      Environmental^ Microbiology/.^
   3. Manuscripts describing new methods or improvements^ in media^ and
      culture conditions will not be considered by JVI^ unless^ the
      procedures are applied to the study of basic problems^ in^
      virology or cell biology. Such manuscripts are more appropriate^
      for /Applied and Environmental Microbiology/ or the /Journal of^
      Clinical Microbiology/. By the same token, manuscripts reporting^
      new methods for the production of monoclonal antibodies will^ not
      be considered unless the methods have been used to address^
      fundamental virologic problems.^
   4. Manuscripts reporting clinical^ investigations, excluding those^
      concerned with the activities^ of antiviral agents, should be^
      submitted to the /Journal of Clinical^ Microbiology/.^
   5. Manuscripts reporting ecological or environmental^ studies are^
      most appropriate for /Applied and Environmental Microbiology/.^
   6. Manuscripts reporting the use of a standard viral vector to^
      elicit an immune response to a nonviral antigen, application^ of a
      virus as a tool to understand a new aspect of immunity,^
      development or better understanding of adjuvants, immunization^
      routes, or duration of immunity, or vaccine trials in humans^
      where efficacy is the focus should be submitted to /Clinical^ and
      Vaccine Immunology/.^

^

We understand that there may be overlap in the scope statements^ of the
ASM journals that publish articles of interest to virologists.^
Questions about these guidelines may be directed to the editor-in-chief^
of the journal being considered.^

If transfer to another ASM journal is recommended by an editor,^ the
corresponding author will be contacted.^

*Note that a manuscript rejected by one ASM journal on scientific^
grounds or on the basis of its general suitability for publication^ is
considered rejected by all other ASM journals.*^


	   EDITORIAL POLICY

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
*Use of Microbiological Information*

The Council Policy Committee (CPC) of the American Society for^
Microbiology affirms the long-standing position of the Society^ that
microbiologists will work for the proper and beneficent^ application of
science and will call to the attention of the^ public or the appropriate
authorities misuses of microbiology^ or of information derived from
microbiology. ASM members are^ obligated to discourage any use of
microbiology contrary to^ the welfare of humankind, including the use of
microbes as biological^ weapons. Bioterrorism violates the fundamental
principles expressed^ in the Code of Ethics of the Society and is
abhorrent to ASM^ and its members.^

ASM recognizes that there are valid concerns regarding the publication^
of information in scientific journals that could be put to
inappropriate^ use as described in the CPC resolution mentioned above.
Members^ of the ASM Publications Board will evaluate the rare
manuscript^ that might raise such issues during the review process.
However,^ as indicated elsewhere in these Instructions, research
articles^ must contain sufficient detail, and material/information must^
be made available, to permit the work to be repeated by others.^ Supply
of materials should be in accordance with laws and regulations^
governing the shipment, transfer, possession, and use of biological^
materials and must be for legitimate, bona fide research needs.^ Links
to, and information regarding, these laws and regulations^ can be found
at http://www.asm.org/Policy/index.asp.^

*General Requirements*

Manuscripts submitted to the journal must represent reports^ of original
research, and the /original data must be available^ for review by the
editor/ if necessary.^

*All authors of a manuscript must have agreed to its submission^ and are
responsible for its content* (initial submission and^ any subsequent
versions), including appropriate citations and^ acknowledgments, and
must also have agreed that the corresponding^ author has the authority
to act on their behalf in all matters^ pertaining to publication of the
manuscript. The corresponding^ author is responsible for obtaining such
agreements and for^ informing the coauthors of the manuscript's status
throughout^ the submission, review, and publication process. For
Authors'^ Corrections and Retractions, signed letters of agreement from^
all of the authors must be submitted (see p. 12-13).^

By submission of a manuscript to the journal, *the authors guarantee^
that they have the authority to publish the work and that the^
manuscript, or one with substantially the same content, was^ not
published previously, is not being considered or published^ elsewhere,
and was not rejected on scientific grounds by another^ ASM journal.*^

It is expected that the authors will provide written assurance^ that
permission to cite unpublished data or personal communications^ has been
granted.^

*By publishing in the journal, the authors agree that, subject^ to
requirements or limitations imposed by laws or governmental^ regulations
of the United States, any DNAs, viruses, microbial^ strains, mutant
animal strains, cell lines, antibodies, and^ similar materials newly
described in the article are available^ from a national collection or
will be made available in a timely^ fashion, at reasonable cost, and in
limited quantities to members^ of the scientific community for
noncommercial purposes. The^ authors guarantee that they have the
authority to comply with^ this policy either directly or by means of
material transfer^ agreements through the owner.*^

*Similarly, the authors agree to make available computer programs,^
originating in the authors' laboratory, that are the only means^ of
confirming the conclusions reported in the article but that^ are not
available commercially. The program(s) and suitable^ documentation
regarding its (their) use may be provided by any^ of the following
means: (i) as a program transmitted via the^ Internet, (ii) as an
Internet server-based tool, or (iii) as^ a compiled or assembled form on
a suitable medium (e.g., magnetic^ or optical). It is expected that the
material will be provided^ in a timely fashion and at reasonable cost to
members of the^ scientific community for noncommercial purposes. The
authors^ guarantee that they have the authority to comply with this
policy^ either directly or by means of material transfer agreements^
through the owner.*^

*Primary Publication*

A scientific paper /or its substance/ published in a serial,
periodical,^ book, conference report, symposium proceeding, or
technical^ bulletin, posted on a nonpersonal website, or made available^
through any other retrievable source, including CD-ROM and other^
electronic forms, is unacceptable for submission to an ASM journal^ on
grounds of prior publication. Work, or its substance, presented^ as a
meeting poster and subsequently reproduced or distributed^ as a "company
white paper" is also unacceptable for submission^ on grounds of prior
publication.^

Posting of a method/protocol on a nonpersonal website should^ not
interfere with the author's ability to have a manuscript^ utilizing that
technique considered for publication in an ASM^ journal; however,
ultimately, it is an editorial decision whether^ the method constitutes
the substance of a paper.^

Posting of a limited amount of original data on a
personal/university/company^ website or websites of small collaborative
groups working on^ a problem does not preclude subsequent submission to,
and publication^ by, an ASM journal. The posted data, however, may not
constitute^ the substance of the submission. Specific questions about
this^ policy may be referred to the Publications Board chairman on^ a
case-by-case basis.^

Posting of theses and dissertations on a personal/university-hosted^
website does not preclude subsequent submission to, and publication^ by,
an ASM journal. Similarly, posting for sale on a commercial^ or similar
website of an /original/, /unmodified/ thesis or dissertation^ (i.e., as
submitted to, and accepted by, the thesis/dissertation^ committee) does
not preclude subsequent submission to, and publication^ by, an ASM
journal.^

Posting of unpublished sequence data on the Internet is usually^ not
considered prior publication; however, the address (URL)^ of the source
of the sequence should be included in the text.^

Preliminary disclosures of research findings webcast as meeting^
presentations or published in abstract form as adjuncts to a^ meeting,
e.g., part of a program, are not considered prior publication.^

It is incumbent upon the author to acknowledge any prior publication,^
including his own articles, of the data contained in a manuscript^
submitted to an ASM journal. A copy of the relevant work should^ be
submitted with the paper as supplemental material.^

Ultimately, it is an editorial decision whether the material^
constitutes the substance of a paper.^

*Permissions*

The corresponding author is responsible for obtaining permission^ from
both the original author and the original publisher (i.e.,^ the
copyright owner) to reproduce or modify figures and tables^ and to
reproduce text (in whole or in part) from previous publications.^

The original *signed* permission(s) must be submitted directly^ to the
editor, outside the Rapid Review system, no later than^ the modification
stage and should be identified as to the relevant^ item in the ASM
manuscript (e.g., "permissions for Fig. 1 in^ JVI00123-08"). In
addition, a statement indicating that the^ material is being reprinted
with permission must be included^ in the relevant figure legend or table
footnote of the manuscript.^ Reprinted text must be enclosed in
quotation marks, and the^ permission statement must be included as
running text or indicated^ parenthetically.^

For supplemental material intended for posting by ASM (see p.^ 5), if
the authors of the JVI manuscript are not also the owners^ of the
supplemental material, the corresponding author *must*^ send to ASM
*signed* permission from the copyright owner that^ allows posting of the
material, as a supplement to the article,^ by ASM. The corresponding
author is also responsible for incorporating^ in the supplemental
material any copyright notices required^ by the owner.^

*Authorship*

An author is one who made a substantial contribution to the^ overall
design and execution of the experiments; therefore,^ *ASM considers all
authors responsible for the entire paper.*^ Individuals who provided
assistance, e.g., supplied strains^ or reagents or critiqued the paper,
need not be listed as authors^ but may be recognized in the
Acknowledgments section.^

A study group, surveillance team, working group, consortium,^ or the
like (e.g., the Active Bacterial Core Surveillance Team)^ may be listed
as a coauthor in the byline if its contributing^ members satisfy the
requirements for authorship and accountability^ as described in these
Instructions. The names (and institutional^ affiliations if desired) of
the contributing members only may^ be given in a footnote keyed to the
study group name in the^ byline or as a separate paragraph in the
Acknowledgments section.^

If the contributing members of the group associated with the^ work do
not fulfill the criteria of substantial contribution^ to and
responsibility for the paper, the group may not be listed^ in the author
byline. Instead, it and the names of its contributing^ members may be
listed in the Acknowledgments section.^

All authors must agree to the order in which their names are^ listed in
the byline. Statements regarding equal contributions^ by two or more
authors (e.g., X.J. and Y.S. contributed equally^ to ... ) are permitted
as footnotes to bylines and must be agreed^ to by all of the authors.
Other statements of attribution may^ be included in the Acknowledgments
section.^

*A change in authorship* (order of listing, addition or deletion^ of a
name, or corresponding author designation) *after submission^ of the
manuscript will be implemented only after receipt of^ signed statements
of agreement from all parties involved.*^

*Disputes about authorship may delay or prevent review and/or^
publication of the manuscript.* Should the individuals involved^ be
unable to reach an accord, review and/or publication of the^ manuscript
can proceed only after the matter is investigated^ and resolved by the
authors' institution(s) and an official^ report of such and signed
statements of agreement are provided^ to ASM.^

*Conflict of Interest*

All authors are expected to disclose, in the manuscript submittal^
letter, any commercial affiliations as well as consultancies,^ stock or
equity interests, and patent-licensing arrangements^ that could be
considered to pose a conflict of interest regarding^ the submitted
manuscript. (Inclusion of a company name in the^ author address lines of
the manuscript does not constitute disclosure.)^ Details of the
disclosure to the editor will remain confidential.^ However, it is the
responsibility of authors to provide, in^ the Acknowledgments section, a
/general/ statement disclosing^ financial or other relationships that
are relevant to the study.^ Examples of potentially conflicting
interests that should be^ disclosed include relationships that might
detract from an author's^ objectivity in presentation of study results,
and interests^ whose value would be enhanced by the results presented.
All^ funding sources for the project, institutional and corporate,^
should be credited in the Acknowledgments section, as described^ below.
In addition, if a manuscript concerns a commercial product,^ the
manufacturer's name must be indicated in the Materials and^ Methods
section or elsewhere in the text, as appropriate, in^ an obvious manner.^

*Copyright*

To maintain and protect the Society's ownership and rights and^ to
continue to afford scientists the opportunity to publish^ in
high-quality journals, ASM requires the corresponding author^ to sign a
copyright transfer agreement on behalf of all the^ authors. This
agreement is sent to the corresponding author^ when the manuscript is
accepted and scheduled for publication.^ Unless this agreement is
executed (/without changes and/or addenda/),^ ASM will not publish the
article.^

In the copyright transfer agreement signed by an author, ASM^ grants to
that author (and coauthors) the right to republish^ /discrete portions/
of his (their) article in any other publication^ (print, CD-ROM, and
other electronic forms) of which he is (they^ are) the author(s) or
editor(s), /on the condition that appropriate^ credit is given to the
original ASM publication/. This republication^ right also extends to
posting on a host computer to which there^ is access via the Internet.
Except as indicated below, significant^ portions of the article may
/not/ be reprinted/posted without^ ASM's prior written permission,
however, as this would constitute^ duplicate publication.^

Authors may post their own published articles on their /personal^ or
university-hosted/ (but not corporate, government, or similar)^ websites
without ASM's prior written permission provided that^ appropriate credit
is given (i.e., either the copyright lines^ shown on the top of the
first page of the PDF version or "Copyright^  American Society for
Microbiology, [insert journal name,^ volume number, page numbers, and
year]" for the HTML version).^

The copyright transfer agreement asks that authors who were^ U.S.
government employees and who wrote the article as part^ of their
employment duties be identified. This is because works^ authored solely
by such U.S. government employees are not subject^ to copyright
protection, so there is no copyright to be transferred.^ The other
provisions of the copyright transfer agreement, such^ as author
representations of originality and authority to enter^ into the
agreement, apply to U.S. government employee-authors^ as well as to
other authors.^

ASM also requires that copyright transfer agreements be signed^ for
cover artwork/photographs.^

Copyright for supplemental material (see p. 5) remains with^ the author,
but a license permitting the posting by ASM will^ be sent, along with
the article copyright transfer agreement,^ to the corresponding author
for signing at the acceptance stage.^ (If the author of the article is
not also the copyright owner^ of the supplemental material, the
corresponding author *must*^ send to ASM *signed* permission from the
owner that allows posting^ of the material, as a supplement to the
article, by ASM. The^ corresponding author is also responsible for
incorporating into^ the supplemental material any copyright notices
required by^ the owner.)^

*Funding Agency Repositories*

The National Institutes of Health (NIH) requests that its grantee^ and
intramural authors provide copies of their accepted manuscripts^ to
PubMed Central (PMC) for posting in the PMC Public Access^ Repository.
ASM allows such JVI authors to do so. ASM also allows^ JVI authors whose
work was supported by similar funding agencies^ that have public access
requirements like those of the NIH (e.g.,^ the Wellcome Trust) to post
their *accepted manuscripts* in publicly^ accessible electronic
repositories maintained by those funding^ agencies. If a funding agency
does not itself maintain such^ a site, then ASM allows the author to
fulfill that requirement^ by depositing the manuscript (*not* the
typeset article) in an^ appropriate institutional or subject-based open
repository established^ by a government or noncommercial entity.^

Since ASM makes the final, typeset articles from its primary-research^
journals available free of charge on the ASM Journals and PMC^ websites
4 months after final publication, ASM recommends that^ when submitting
the accepted manuscript to PMC or a similar^ public access site, the
author specify that the *posting release^ date for the manuscript be no
earlier than 4 months after publication^ of the typeset article by ASM.*^

*Use of Human Subjects or Animals in Research*

The use of human subjects or other animals for research purposes^ is
regulated by the federal government and individual institutions.^
Manuscripts containing information related to human or animal^ use
should clearly state that the research has complied with^ all relevant
federal guidelines and institutional policies.^ Copies of these
guidelines and policy statements must be available^ for review by the
editor if necessary.^

*Patient Identification*

When isolates are derived from patients in clinical studies,^ do not
identify them by using the patients' initials, even as^ part of a strain
designation. Change the initials to numerals^ or use randomly chosen
letters. Do not give hospital unit numbers;^ if a designation is needed,
use only the last two digits of^ the unit. (Note: Established
designations of some viruses and^ cell lines, although they consist of
initials, are acceptable^ [e.g., JC virus, BK virus, and HeLa cells].)^

*Nucleotide and Amino Acid Sequences*

It is expected that newly determined nucleotide and/or amino^ acid
sequence data will be deposited and GenBank/EMBL/DDBJ accession^ numbers
will be included in the manuscript no later than the^ modification stage
of the review process. It is also expected^ that the sequence data will
be released to the public no later^ than the publication (online
posting) date of the accepted manuscript.^ The accession numbers should
be included in a separate paragraph^ at the end of the Materials and
Methods section for full-length^ papers or at the end of the text for
Notes. If conclusions in^ a manuscript are based on the analysis of
sequences and a GenBank/EMBL/DDBJ^ accession number is not provided at
the time of the review,^ authors should provide the sequence data as
supplemental material.^

It is expected that, when previously published sequence accession^
numbers are cited in a manuscript, the original citations (e.g.,^
journal articles) will be included in the References section^ when
possible or reasonable.^

Authors are also expected to do elementary searches and comparisons^ of
nucleotide and amino acid sequences against the sequences^ in standard
databases (e.g., GenBank) immediately before manuscripts^ are submitted
and again at the proof stage.^

Analyses should specify the database, and the date of each analysis^
should be indicated as, e.g., January 2008. If relevant, the^ version of
the software used should be specified.^

See p. 15 for nucleic acid sequence formatting instructions.^

The URLs of the databases mentioned above are as follows: DNA^ Data Bank
of Japan (DDBJ), http://www.ddbj.nig.ac.jp/; EMBL^ Nucleotide Sequence
Database (EMBL), http://www.ebi.ac.uk/embl/;^ and GenBank, National
Center for Biotechnology Information (GenBank),^
http://www.ncbi.nlm.nih.gov/.^

*Structural Determinations*

It is expected that coordinates for new structures of macromolecules^
will be deposited in the Protein Data Bank and that assigned^
identification codes will be included in the manuscript no later^ than
the modification stage of the review process. It is also^ expected that
the coordinates will be released to the public^ no later than the
publication (online posting) date of the accepted^ manuscript. Authors
are encouraged to send coordinates with^ their original submission,
however, so that reviewers can examine^ them along with the manuscript.
The accession number(s) should^ be listed in a separate paragraph at the
end of the Materials^ and Methods section for full-length papers or at
the end of^ the text for Notes.^

The URLs for coordinate deposition are http://rcsb-deposit.rutgers.edu/^
and http://pdbdep.protein.osaka-u.ac.jp/.^

*Microarray Data*

It is expected that the entire set of supporting microarray^ data will
be deposited in the appropriate public database (e.g.,^ GEO,
ArrayExpress, or CIBEX) and that the assigned accession^ number(s) will
be included in the manuscript no later than the^ modification stage of
the review process. It is also expected^ that the data will be released
to the public no later than the^ publication (online posting) date of
the accepted manuscript.^ Authors are encouraged to send the relevant
data with their^ original submission, however, so that reviewers can
examine^ them along with the manuscript. The accession number(s) should^
be listed in a separate paragraph at the end of the Materials^ and
Methods section for full-length papers or at the end of^ the text for
Notes.^

The URLs of the databases mentioned above are as follows: Gene^
Expression Omnibus (GEO), http://www.ncbi.nlm.nih.gov/projects/geo/;^
ArrayExpress, http://www.ebi.ac.uk/arrayexpress/?#ae=main[0];^ and
Center for Information Biology Gene Expression Database^ (CIBEX),
http://cibex.nig.ac.jp/index.jsp.^

*Supplemental Material*

Supplemental material intended for posting by ASM may not include^
additional figures or tables that simply support the authors'^
conclusions. It must be restricted to large or complex data^ sets or
results that cannot readily be displayed in printed^ form because of
space or technical limitations. Such material^ may include data from
microarray, structural, biochemical, or^ video imaging analyses. In such
cases, the manuscript submitted^ for review should include a
distillation of the results so that^ the principal conclusions are fully
supported without referral^ to the supplemental material.^

Supplemental material intended for posting by ASM must be uploaded^ in
Rapid Review and will be reviewed along with the manuscript.^ The
maximum size permitted for an individual file is 25 MB.^ If your file
exceeds this size, you must use a file compression^ utility (e.g.,
WinZip or Stuffit) to reduce the size below 25^ MB. The decision to
publish (i.e., post online only) the material^ with the article if it is
accepted will be made by the editor^ and conveyed to the corresponding
author in the acceptance e-mail.^ Therefore, it is possible that a
manuscript will be accepted^ but that the supplemental material will not
be.^

If the software required for users to view/use the supplemental^
material is not embedded in the file, you are urged to use shareware^ or
generally available/easily accessible programs.^

Unlike the manuscript, supplemental material will *not* be edited^ by
the ASM Journals staff and proofs will not be made available.^
References related to supplemental material *only* should not^ be listed
in the References section of an article; instead,^ include them with the
supplemental material hosted by ASM or^ posted on a
personal/institutional website.^

Supplemental material will always remain associated with its^ article
and is *not* subject to any modifications after publication.^

Material that has been published previously (print or online)^ is not
acceptable for posting as supplemental material. Instead,^ the
appropriate reference(s) to the original publication should^ be made in
the manuscript text.^

Copyright for the supplemental material remains with the author,^ but a
license permitting the posting by ASM will be sent, along^ with the
article copyright transfer agreement, to the corresponding^ author for
signing. If you are not the copyright owner, you^ *must* provide to ASM
*signed* permission from the owner that allows^ posting of the material,
as a supplement to your article, by^ ASM. You are responsible for
including in the supplemental material^ any copyright notices required
by the owner.^

*A one-time charge (amount not yet determined) may be levied^ for
posting of supplemental material. When instituted, the charge^ will be
indicated in the ASM acceptance letter.*^

*Compliance*

Failure to comply with the policies described in these Instructions^ may
result in a letter of reprimand, a suspension of publishing^ privileges
in ASM journals, and/or notification of the authors'^ institutions.^

Authors employed by companies whose policies do not permit them^ to
comply with the ASM policies may be sanctioned as individuals^ and/or
ASM may refuse to consider manuscripts having authors^ from such
companies.^

*Warranties and Exclusions*

Articles published in this journal represent the opinions of^ the
authors and do not necessarily represent the opinions of^ ASM. ASM does
not warrant the fitness or suitability, for any^ purpose, of any
methodology, kit, product, or device described^ or identified in an
article. The use of trade names is for identification^ purposes only and
does not constitute endorsement by ASM.^

*Page Charges*

Authors whose research was supported by grants, special funds^
(including departmental and institutional), or contracts (including^
governmental) or whose research was done as part of their official^
duties (government, corporate, etc.) are required to pay page^ charges
(based on the number of typeset pages, including illustrations,^ in the
article).^

For a *corresponding author who is an ASM member*, page charges^ are
currently $65 per page for the first eight pages and $200^ per page for
each page in excess of eight (subject to change^ without notice). To
obtain the member rate, the /corresponding^ author/ must be an ASM member.^

For a *nonmember corresponding author*, page charges are currently^ $75
per page for the first eight pages and $250 for each page^ in excess of
eight (subject to change without notice). A corresponding^ author who is
not an ASM member may join ASM to obtain the member^ rate.^

If the research was not supported by any of the means described^ above,
a request to waive the charges may be mailed (Journals^ Department, ASM,
1752 N St., N.W., Washington, DC 20036-2904,^ USA) or faxed
(202-942-9355) to the Journals Department. This^ request must indicate
how the work was supported and should^ be accompanied by copies of the
title page and Acknowledgments^ section.^

Minireviews, Guest Commentaries, and Comment Letters to the^ Editor are
not subject to page charges. New-Data Letters to^ the Editor /are/
subject to page charges.^

*Editorial Style*

The editorial style of ASM journals conforms to the /ASM Style^ Manual
for Journals/ (American Society for Microbiology, 2008,^ in-house
document) and /How To Write and Publish a Scientific^ Paper/, 6th ed.
(Greenwood Press, Westport, CT, 2006), as interpreted^ and modified by
the editors and the ASM Journals Department.^

The editors and the Journals Department reserve the privilege^ of
editing manuscripts to conform with the stylistic conventions^ set forth
in the aforesaid publications and in these Instructions.^

*Review Process*

All manuscripts are considered to be confidential and are reviewed^ by
the editors, members of the editorial board, or qualified^ ad hoc
reviewers.^

To expedite the review process, authors *must* recommend at least^ five
reviewers who have expertise in the field, who are not^ members of their
institution(s), who have not recently been^ associated with their
laboratory(ies), and who could not otherwise^ be considered to pose a
conflict of interest regarding the submitted^ manuscript. At least three
of the recommended reviewers *must*^ be editorial board members. Please
provide, where indicated^ on the submission form, contact information
for suggested reviewers^ who are not editorial board members.^

/Copies of in-press and submitted manuscripts that are important^ for
judgment of the present manuscript should be included as^ supplemental
material to facilitate the review./^

When a manuscript is submitted to the journal, it is given a^ number
(e.g., JVI00047-08 version 1) and assigned to one of^ the editors.
*(Always refer to this number in communications^ with the editor and the
Journals Department.)* /It is the responsibility^ of the corresponding
author to inform the coauthors of the manuscript's^ status throughout
the submission, review, and publication processes/.^ The reviewers
operate under strict guidelines set forth in "Guidelines^ for Reviewers"
(http://www.journals.asm.org/misc/reviewguide.shtml)^ and are expected
to complete their reviews expeditiously.^

The corresponding author is notified, generally within 4 to^ 6 weeks
after submission, of the editor's decision to accept,^ reject, or
require modification. When modification is requested,^ the corresponding
author must either submit the modified version^ within 2 months or
withdraw the manuscript. A point-by-point^ response to the reviews must
be provided in the designated section^ of the Rapid Review submission
form for the revised manuscript,^ and a compare copy of the manuscript
(without figures) should^ be included as supplemental material if the
editor requested^ one.^

Manuscripts that have been rejected, or withdrawn after being^ returned
for modification, may be resubmitted to the same ASM^ journal if the
major criticisms have been addressed. A manuscript^ rejected by one ASM
journal on scientific grounds or on the^ basis of its general
suitability for publication is considered^ rejected by /all/ other ASM
journals; however, a manuscript rejected^ solely on the basis of scope
may be "resubmitted" to a more^ appropriate ASM journal. A manuscript is
considered a resubmission^ no matter how much (or little) it differs
from the rejected^ or withdrawn manuscript and regardless of how much
time has^ passed.^

For *all* resubmissions (to the same or a different journal, and^
irrespective of the extent of the revisions and irrespective^ of the
amount of time between rejection and resubmission), the^ cover letter
*must* state that the manuscript is a resubmission,^ and the former
manuscript number *must* be provided in the appropriate^ field on the
submission form. A point-by-point response to the^ review(s) and a
compare copy of the revised manuscript showing^ the changes *must* be
included as supplemental material (the Rebuttal^ section appears in the
submission form only if the manuscript^ is a modification). Manuscripts
resubmitted to the same journal^ are normally handled by the original
editor.^

*Rejected manuscripts may be resubmitted only once unless permission^
has been obtained from the original editor or from the editor^ in chief.*^

*Notification of Acceptance*

When an editor has decided that a manuscript is acceptable for^
publication on the basis of scientific merit, the author and^ the
Journals Department are notified. A PDF version of the accepted^
manuscript is posted online as soon as possible (see below).^

The text files undergo an automated preediting, cleanup, and^ tagging
process specific to the particular article type, and^ the illustrations
are examined. If all files have been prepared^ according to the criteria
set forth in these Instructions and^ those in Rapid Review, the
acceptance procedure will be completed^ successfully. If there are
problems that would cause extensive^ corrections to be made at the
copyediting stage or if the files^ are not acceptable for production,
ASM Journals staff will contact^ the corresponding author. Once all the
material intended for^ publication has been determined to be adequate,
the manuscript^ is scheduled for the next available issue and an
acceptance^ letter indicating the month of publication, approximate
page^ proof dates, and table of contents section is mailed to the^
corresponding author; a copyright transfer agreement is also^ included,
as is a license to permit posting of supplemental^ material (if
applicable). The editorial staff of the ASM Journals^ Department
completes the editing of the manuscript to bring^ it into conformity
with prescribed standards.^

*Publish ahead of Print*

For its primary-research journals, ASM posts online PDF versions^ of
manuscripts that have been peer reviewed and accepted but^ not yet
copyedited. This feature is called "[journal acronym]^ Accepts" (e.g.,
JVI Accepts) and is accessible from the Journals^ website. The
manuscripts are published online as soon as possible^ after acceptance,
on a weekly basis, before the copyedited,^ typeset articles are
published. They are posted "*as is*" (i.e.,^ as submitted by the authors
at the modification stage) and do^ not reflect ASM editorial changes.
*No corrections/changes to^ the PDF manuscripts are accepted*.
Accordingly, there likely^ will be differences between the JVI Accepts
manuscripts and^ the final, typeset articles. The manuscripts remain
listed on^ the JVI Accepts page until the final, typeset articles are
posted.^ At that point, the manuscripts are removed from the JVI
Accepts^ page and become available only through links from the final,^
typeset articles. The manuscripts are under subscription access^ control
until 4 months after the typeset articles are posted,^ when free access
is provided to everyone (subject to the applicable^ ASM license terms
and conditions). Supplemental material intended,^ and accepted, for
publication is not posted until publication^ of the final, typeset
article.^

Instructions on how to cite such manuscripts may be found in^ the
"References" section below (p. 10).^

*Page Proofs*

Page proofs, together with a query sheet and instructions for^ handling
proofs, will be made available to the corresponding^ author
electronically via a PDF file that can be accessed through^ a unique
password. Since corresponding authors will be notified^ of the
availability of their PDF proofs, instructed how to access^ information
about page charges, reprints, and color figure charges^ (if applicable),
and assigned their unique password via e-mail,^ an e-mail address *must*
be supplied in the correspondent footnote.^ Failure to do so may result
in a delay in publication. *The PDF^ page proofs must be printed out,
and corrections must be written^ on the hard copy*. Queries must be
answered on the query page^ or on a separate sheet of paper, and any
changes related to^ the queries must be indicated on the proofs. Note
that the copy^ editor does not query at every instance where a change
has been^ made. Queries are written only to request necessary
information^ or clarification of an unclear passage or to draw
attention^ to edits that may have altered the sense. It is the author's^
responsibility to read the entire text, tables, and figure legends,^ not
just items queried. As soon as the page proofs are corrected^ and signed
by the person who proofread them (within 48 h), *they^ should be mailed
or sent by a courier service* such as FedEx,^ *not* faxed or sent as an
e-mail attachment, to the ASM Journals^ Department.^

The proof stage is not the time to make extensive corrections,^
additions, or deletions. Important new information that has^ become
available between acceptance of the manuscript and receipt^ of the
proofs may be inserted as an addendum in proof with the^ permission of
the editor. If references to unpublished data^ or personal
communications are added, it is expected that written^ assurance
granting permission for the citation will be included.^ Limit changes to
correction of spelling errors, incorrect data,^ and grammatical errors
and updated information for references^ to manuscripts that have been
submitted or are in press. If^ URLs have been provided in the article,
recheck the sites to^ ensure that the addresses are still accurate and
the material^ that you expect the reader to find is indeed there.^

Questions about /late proofs and problems in the proofs/ should^ be
directed to the ASM Journals Department (telephone, 202-942-9234).^
Questions about /accessing or viewing your PDF proofs/ should^ be
directed to Katie Gay of Cadmus Communications at 804-261-3155^ or
gayk@cadmus.com <mailto:gayk@cadmus.com>.^

*Reprints*

Reprints (in multiples of 100) may be purchased by all coauthors.^ In
the proof notification e-mail, the corresponding author will^ be
instructed how to access information about reprints.^

The corresponding authors of Minireviews and Guest Commentaries^ may
receive 100 free reprints of their contribution; additional^ reprints
(in multiples of 100) may be purchased if desired.^ As for regular
articles, the corresponding author will be instructed,^ in the proof
notification e-mail, how to access information^ about reprints.^

*PDF Files*

A corresponding author who has included an e-mail address in^ his
"corresponding author" footnote will have limited access^ (10 downloads,
total) to the PDF file of his published article.^ An e-mail alert will
automatically be sent to him on the day^ the issue is posted. It will
provide a URL, which will be required^ to obtain access, and
instructions. An article may be viewed,^ printed, or stored, provided
that it is for the author's own^ use.^

Should coauthors or colleagues be interested in viewing the^ paper for
their own use, the corresponding author may provide^ them with the URL;
a copy of the article may not be forwarded^ electronically. However,
they must be made aware of the terms^ and conditions of the ASM
copyright. (For details, go to
http://www.journals.asm.org/misc/terms.shtml.)^ Note that each such
download will count toward the corresponding^ author's total of 10.
After 10 downloads, access will be denied^ and can be obtained only
through a subscription to the journal^ (either individual or
institutional) or after the standard access^ control has been lifted
(i.e., 4 months after publication).^


	   HOW TO SUBMIT MANUSCRIPTS

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
All submissions to JVI must be made electronically via the Rapid^ Review
online submission and peer review system at the following^ URL:
https://www.rapidreview.com/ASM2/CALogon.jsp. (E-mailed^ submissions
will not be accepted.) First-time users must create^ an Author account,
which may be used for submitting to all ASM^ journals. Instructions for
creating an Author account are available^ at the above URL under the
Create Account button. Step-by-step^ instructions for submitting a
manuscript via Rapid Review are^ available from the account holder's My
Manuscripts page. Information^ on file types acceptable for electronic
submission can be found^ under the More About File Formats button.^

PDFs of submitted manuscripts are retained in Rapid Review for^ 1 to 2
years, after which they are deleted.^


	   ORGANIZATION AND FORMAT

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
On receipt at ASM, an accepted manuscript undergoes an automated^
preediting, cleanup, and tagging process specific to the particular^
article type. To optimize this process, manuscripts must be^ supplied in
the correct format and with the appropriate sections^ and headings.^

Type every portion of the manuscript double spaced (a minimum^ of 6 mm
between lines), including figure legends, table footnotes,^ and
References, and number all pages in sequence, including^ the abstract,
figure legends, and tables. Place the last two^ items after the
References section. *Manuscript pages should^ have line numbers;
manuscripts without line numbers may be editorially^ rejected by the
editor, with a suggestion of resubmission after^ line numbers are
added.* The font size should be no smaller than^ 12 points. It is
recommended that the following sets of characters^ be easily
distinguishable in the manuscript: the numeral zero^ (0) and the letter
"oh" (O); the numeral one (1), the letter^ "el" (l), and the letter
"eye" (I); and a multiplication sign^ (x) and the letter "ex" (x). Do
not create symbols as graphics^ or use special fonts that are external
to your word processing^ program; use the "insert symbol" function. Set
the page size^ to 81/2 by 11 inches (ca. 21.6 by 28 cm). Italicize or
underline^ any words that should appear in italics, and indicate
paragraph^ lead-ins in bold type.^

Authors who are unsure of proper English usage should have their^
manuscripts checked by someone proficient in the English language.^

*Manuscripts may be editorially rejected, without review, on^ the basis
of poor English or lack of conformity to the standards^ set forth in
these Instructions.*^

*Full-Length Papers*

Full-length papers should include the elements described in^ this section.^

*Title, running title, and byline.* Each manuscript should present the
results of an independent,^ cohesive study; thus, numbered series titles
are not allowed.^ Avoid the main title/subtitle arrangement, complete
sentences,^ and unnecessary articles. On the title page, include the
title,^ running title (not to exceed 54 characters and spaces), name^ of
each author, address(es) of the institution(s) at which the^ work was
performed, each author's affiliation, and a footnote^ indicating the
present address of any author no longer at the^ institution where the
work was performed. Place an asterisk^ after the name of the author to
whom inquiries regarding the^ paper should be addressed (see
"Correspondent footnote" below).^

Also include on the title page the word count for the abstract^ and the
word count for the text (excluding the references, table^ footnotes, and
figure legends).^

*Study group in byline.* A study group, surveillance team, working
group, consortium,^ or the like (e.g., the Active Bacterial Core
Surveillance Team)^ may be listed as a coauthor in the byline if its
contributing^ members satisfy the requirements for authorship and
accountability^ as described in these Instructions. The names (and
institutional^ affiliations if desired) of the contributing members may
be^ given in a footnote keyed to the study group name in the byline^ or
as a separate paragraph in Acknowledgments.^

If the contributing members of the group associated with the^ work do
not fulfill the criteria of substantial contribution^ to and
responsibility for the paper, the group may not be listed^ in the author
byline. Instead, it and the names of its contributing^ members may be
listed in the Acknowledgments section.^

*Correspondent footnote.* The complete mailing address, a single
telephone number, a single^ fax number, and a single e-mail address for
the corresponding^ author should be included on the title page of the
manuscript.^ This information will be published in the article as a
footnote^ to facilitate communication, and the e-mail address will be^
used to notify the corresponding author of the availability^ of proofs
and, later, of the PDF file of the published article.^

*Abstract.* Limit the abstract to *250 words or fewer* and concisely
summarize^ the basic content of the paper without presenting extensive^
experimental details. Avoid abbreviations and references, and^ do not
include diagrams. When it is essential to include a reference,^ use the
same format as shown for the References section but^ omit the article
title. Because the abstract will be published^ separately by abstracting
services, it must be complete and^ understandable without reference to
the text.^

*Introduction.* The introduction should supply sufficient background
information^ to allow the reader to understand and evaluate the results
of^ the present study without referring to previous publications^ on the
topic. The introduction should also provide the hypothesis^ that was
addressed or the rationale for the present study. Choose^ references
carefully to provide the most salient background^ rather than an
exhaustive review of the topic.^

*Materials and Methods.* The Materials and Methods section should
include sufficient^ technical information to allow the experiments to be
repeated.^ When centrifugation conditions are critical, give enough
information^ to enable another investigator to repeat the procedure:
make^ of centrifuge, model of rotor, temperature, time at maximum^
speed, and centrifugal force (x /g/ rather than revolutions per^
minute). For commonly used materials and methods (e.g., media^ and
protein concentration determinations), a simple reference^ is
sufficient. If several alternative methods are commonly used,^ it is
helpful to identify the method briefly as well as to cite^ the
reference. For example, it is preferable to state "cells^ were broken by
ultrasonic treatment as previously described^ (9)" rather than to state
"cells were broken as previously described^ (9)." This allows the reader
to assess the method without constant^ reference to previous
publications. Describe new methods completely^ and give sources of
unusual chemicals, equipment, or microbial^ strains. When large numbers
of microbial strains or mutants^ are used in a study, include tables
identifying the immediate^ sources (i.e., sources from whom the strains
were obtained)^ and properties of the strains, mutants, bacteriophages,
plasmids,^ etc.^

A method, strain, etc., used in only one of several experiments^
reported in the paper may be described in the Results section^ or very
briefly (one or two sentences) in a table footnote or^ figure legend. It
is expected that the sources from whom the^ strains were obtained will
be identified.^

*Results.* In the Results section, include the rationale or design of
the^ experiments as well as the results; reserve extensive
interpretation^ of the results for the Discussion section. Present the
results^ as concisely as possible in *one* of the following: text,
table(s),^ or figure(s). Data in tables (e.g., cpm of radioactivity)
should^ not contain more significant figures than the precision of the^
measurement allows. Illustrations (particularly photomicrographs^ and
electron micrographs) should be limited to those that are^ absolutely
necessary to show the experimental findings. Number^ figures and tables
in the order in which they are cited in the^ text, and be sure to cite
all figures and tables.^

*Discussion.* The Discussion should provide an interpretation of the
results^ in relation to previously published work and to the
experimental^ system at hand and should not contain extensive repetition
of^ the Results section or reiteration of the introduction. In short^
papers, the Results and Discussion sections may be combined.^

*Acknowledgments.* The source of any financial sup-port received for the
work being^ published must be indicated in the Acknowledgments section.^
(It will be assumed that the absence of such an acknowledgment^ is a
statement by the authors that no support was re-ceived.)^ The usual
format is as follows: "This work was supported by^ Public Health Service
grant CA-01234 from the National Cancer^ Institute."^

Recognition of personal assistance should be given as a separate^
paragraph, as should any statements disclaiming endorsement^ or approval
of the views reflected in the paper or of a product^ mentioned therein.^

*Appendixes.* Appendixes, which contain additional material to aid the
reader,^ are permitted. Titles, authors, and References sections that^
are distinct from those of the primary article are not allowed.^ If it
is not feasible to list the author(s) of the appendix^ in the byline or
the Acknowledgments section of the primary^ article, rewrite the
appendix so that it can be considered for^ publication as an independent
article, either full-length or^ Note style. Equations, tables, and
figures should be labeled^ with the letter "A" preceding the numeral to
distinguish them^ from those cited in the main body of the text.^

*References.* *(i) References listed in the References section.* The
References^ section must include all journal articles (both print and
online),^ books and book chapters (both print and online), patents,
theses^ and dissertations, published conference proceedings, meeting^
abstracts from published abstract books or journal supplements,^ letters
(to the editor), and company publications, as well as^ in-press journal
articles, book chapters, and books (publication^ title must be given).
Arrange the citations in *alphabetical^ order* (letter by letter,
ignoring spaces and punctuation) by^ first author and *number
consecutively*. Provide the names of^ *all* the authors for each
reference. All listed references *must*^ be cited parenthetically by
number in the text. Since title^ and byline information that is
downloaded from PubMed does not^ always show accents, italics, or
special characters, authors^ should refer to the PDF files or hard-copy
versions of the articles^ and incorporate the necessary corrections in
the submitted manuscript.^ Abbreviate journal names according to the
/List of Journals Indexed^ for Medline/ (National Library of Medicine,
National Institutes^ of Health, 2007; available at
ftp://nlmpubs.nlm.nih.gov/online/journals/ljiweb.pdf),^ the primary
source for ASM style.^

Follow the styles shown in the examples below for print references.^

   1. *Arendsen, A. F., M. Q. Solimar, and S. W. Ragsdale.* 1999.
      Nitrate-dependent^ regulation of acetate biosynthesis and nitrate
      respiration by^ /Clostridium thermoaceticum/. J. Bacteriol.
      *181:*1489-1495.^
   2. *Cox,^ C. S., B. R. Brown, and J. C. Smith.* J. Gen. Genet., in^
      press.*^ {/Article title is optional; journal title is mandatory./}^
   3. *da^ Costa, M. S., M. F. Nobre, and F. A. Rainey.* 2001. Genus^
      I.^ Thermus Brock and Freeze 1969, 295,^AL emend. Nobre, Trper^
      and da Costa 1996b, 605, p. 404-414. /In/ D. R. Boone, R. W.
      Castenholz,^ and G. M. Garrity (ed.), Bergey's manual of
      systematic bacteriology,^ 2nd ed., vol. 1. Springer, New York, NY.^
   4. *Elder, B. L., and^ S. E. Sharp.* 2003. Cumitech 39, Competency^
      assessment in the^ clinical laboratory. Coordinating ed., S.^ E.
      Sharp. ASM Press,^ Washington, DC.^
   5. *Falagas, M. E., and S. K. Kasiakou.* 2006.^ Use of international^
      units when dosing colistin will help decrease^ confusion related^
      to various formulations of the drug around^ the world.
      Antimicrob.^ Agents Chemother. *50:*2274-2275. (Letter.)^
      {/"Letter" or "Letter^ to the editor" is allowed but not required^
      at the end of such^ an entry./}^
   6. *Fitzgerald, G., and D. Shaw.*^ /In/ A. E. Waters (ed.), Clinical^
      microbiology, in press. EFH^ Publishing Co., Boston, MA.*
      {/Chapter^ title is optional./}^
   7. *Forman,^ M. S., and A. Valsamakis.* 2003. Specimen collection,^
      transport,^ and processing: virology, p. 1227-1241. /In/ P. R.^
      Murray, E.^ J. Baron, M. A. Pfaller, J. H. Jorgensen, and R.^ H.
      Yolken (ed.),^ Manual of clinical microbiology, 8th ed. ASM^
      Press, Washington,^ DC.^
   8. *Garcia, C. O., S. Paira, R. Burgos, J. Molina, J. F. Molina,^ and
      C. Calvo.* 1996. Detection of salmonella DNA in synovial^ membrane
      and synovial fluid from Latin American patients. Arthritis^ Rheum.
      *39*(Suppl.)*:*S185. {/Meeting abstract published in journal^
      supplement./}^
   9. *Green, P. N., D. Hood, and C. S. Dow.* 1984. Taxonomic^ status^
      of some methylotrophic bacteria, p. 251-254. /In/ R. L.^ Crawford^
      and R. S. Hanson (ed.), Microbial growth on C_1 compounds.^
      Proceedings^ of the 4th International Symposium. American Society^
      for Microbiology,^ Washington, DC.^
  10. *Odell, J. C.* April 1970.^ Process for batch culturing. U.S.
      patent^ 484,363,770. {/Include^ the name of the patented
      item/process^ if possible; the patent^ number is mandatory./}^
  11. *O'Malley, D. R.* 1998. Ph.D. thesis.^ University of California,^
      Los Angeles. {/Title is optional./}^
  12. *Rotimi, V. O., N. O. Salako, E. M. Mohaddas, and L. P. Philip.*^
      2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.,^
      abstr. D-1658. {/Abstract title is optional./}^
  13. *Smith, D., C.^ Johnson, M. Maier, and J. J. Maurer.* 2005.
      Distribution^ of fimbrial,^ phage and plasmid associated virulence
      genes among^ poultry /Salmonella^ enterica/ serovars, abstr.
      P-038, p. 445.^ Abstr. 105th Gen. Meet.^ Am. Soc. Microbiol.
      American Society^ for Microbiology, Washington,^ DC. {/Abstract
      title is optional./}^
  14. *Stratagene.* 2006. Yeast^ DNA isolation system: instruction
      manual.^ Stratagene, La Jolla,^ CA. {/Use the company name as the
      author^ if none is provided^ for a company publication./}^

^

*A reference to an in-press ASM publication should state the^ control
number (e.g., JVI00577-08) if it is a journal article^ or the name of
the publication if it is a book.^

Online references must provide the same information that print^
references do, but some variation is allowed. For online journal^
articles, posting or revision dates may replace the year of^
publication, and a DOI or URL may be provided in addition to^ or in lieu
of volume and page numbers. Some examples follow.^

   1. *Charlier, D., and N. Glansdorff.* September 2004, posting date.^
      Chapter 3.6.1.10, Biosynthesis of arginine and polyamines. /In/^
      R. Curtiss III et al. (ed.), EcoSal?/Escherichia coli/ and^
      /Salmonella/: cellular and molecular biology. ASM Press,
      Washington,^ DC. http://www.ecosal.org/ecosal/index.jsp. {/Note
      that each^ chapter has its own posting date./}^
   2. *Dionne, M. S., and D. S.^ Schneider.* 2002. Screening the
      fruitfly^ immune system. Genome^ Biol. *3:* REVIEWS1010.
      http://genomebiology.com/2002/3/4/reviews/1010.^
   3. *Smith, F. X., H. J. Merianos, A. T. Brunger, and D. M.
      Engelman.*^ 2001. Polar residues drive association of polyleucine
      transmembrane^ helices. Proc. Natl. Acad. Sci. USA *98:*
      2250-2255. doi:10.1073/pnas.041593698.^
   4. *Winnick, S., D. O. Lucas, A. L. Hartman, and D. Toll.* 2005.^ How
      do you improve compliance? Pediatrics *115:* e718-e724.^

^

NOTE: A posting or accession date is required for any online^ reference
that is periodically updated or changed.^

*(ii) References cited in the text.* References to unpublished^ data,
manuscripts submitted for publication, unpublished conference^
presentations (e.g., a report or poster that has not appeared^ in
published conference proceedings), personal communications,^ patent
applications and patents pending, computer software,^ databases, and
websites (home pages) should be made parenthetically^ in the text as
follows.^

... similar results (R. B. Layton and C. C. Weathers, unpublished^ data).^

... system was used (J. L. McInerney, A. F. Holden, and P. N.^ Brighton,
submitted for publication).^

... as described previously (M. G. Gordon and F. L. Rattner,^ presented
at the Fourth Symposium on Food Microbiology, Overton,^ IL, 13 to 15
June 1989). {/For nonpublished abstracts, posters,^ etc./}^

... this new process (V. R. Smoll, 20 June 1999, Australian^ Patent
Office). {/For non-U.S. patent applications, give the^ date of
publication of the application./}^

... available in the GenBank database
(http://www.ncbi.nlm.nih.gov/Genbank/index.html).^

... using ABC software (version 2.2; Department of Microbiology,^ State
University [http://www.stu.micro]).^

*URLs for companies that produce any of the products mentioned^ in your
study or for products being sold may NOT be included^ in the article.
However, company URLs that permit access to^ scientific data related to
the study or to shareware used in^ the study are permitted.*^

*(iii) References related to supplemental material.* References^ that
are related *only* to supplemental material hosted by ASM^ or posted on
a personal/institutional website should not be^ listed in the References
section of an article; include them^ with the supplemental material
itself.^

*(iv) Referencing publish-ahead-of-print manuscripts.* Citations^ of ASM
Accepts manuscripts should look like the following example.^

*Wang, G. G., M. P. Pasillas, and M. P. Kamps.* 15 May 2006. Persistent^
transactivation by Meis1 replaces Hox function in myeloid
leukemogenesis^ models: evidence for co-occupancy of Meis1-Pbx and
Hox-Pbx complexes^ on promoters of leukemia-associated genes. Mol. Cell.
Biol.^ doi:10.1128/MCB.00586-06.^

If an author of an article cites an ASM Accepts manuscript in^ his paper
but wishes at the proof stage to change the reference^ entry to that for
the published article, the following style^ should be used:^

*Wang, G. G., M. P. Pasillas, and M. P. Kamps.* 15 May 2006. Persistent^
transactivation by Meis1 replaces Hox function in myeloid
leukemogenesis^ models: evidence for co-occupancy of Meis1-Pbx and
Hox-Pbx complexes^ on promoters of leukemia-associated genes. Mol. Cell.
Biol.^ doi:10.1128/MCB.00586-06. (Subsequently published, Mol. Cell.^
Biol. *26:* 3902-3916, 2006.)^

Other journals may use different styles for their
publish-ahead-of-print^ manuscripts, but citation entries must include
the following^ information: author name(s), posting date, title, journal
title,^ and volume and page numbers and/or DOI. The following is an^
example:^

*Zhou, F. X., H. J. Merianos, A. T. Brunger, and D. M. Engelman.*^ 13
February 2001, posting date. Polar residues drive association^ of
polyleucine transmembrane helices. Proc. Natl. Acad. Sci.^ USA
doi:10.1073/pnas.041593698.^

*Notes*

The Note format is intended for the presentation of brief observations^
that do not warrant full-length papers. Submit Notes in the^ same way as
full-length papers. /They receive the same review,^ they are not
published more rapidly than full-length papers,^ and they are not
considered preliminary communications/.^

Each Note must have an *abstract of no more than 100 words.* Do^ not use
section headings in the body of the Note; combine methods,^ results, and
discussion in a single section. Paragraph lead-ins^ are permissible. The
text should be kept to a minimum and *should^ not exceed 1,600 words*
(include the word count on the manuscript^ title page); the total number
of figures and tables should not^ exceed four. *Materials and methods
should be described in the^ text, not in figure legends or table
footnotes.* Present acknowledgments^ as in full-length papers, but do
not use a heading. The References^ section is identical to that of
full-length papers.^

*Minireviews*

Minireviews are brief (*limit of 6 printed pages exclusive of^
references*) summaries of important developments in virology^ research.
They must be based on published articles and may address^ any subject
within the scope of the journal.^

Minireviews are solicited by the Minireview editor and are subject^ to
review. Unsolicited reviews will not be considered. Ideas^ for
Minireviews may be sent to the Minireview editor. Manuscripts^ should be
submitted via Rapid Review.^

Minireviews do not have abstracts. In the Abstract section of^ the
submission form, put "Not Applicable." The body of the Minireview^ may
either have section headings or be set up like a Note (see^ above).^

*Guest Commentaries*

Guest Commentaries are invited communications written in response^ to
invitations issued by the editors and concern topics of interest^ to the
broad readership of the journal that are not necessarily^ covered by
Minireviews. They should raise issues of interest^ to the community of
virologists, initiate or focus discussion,^ or propose position or
consensus statements for leadership groups^ in research. Review of the
literature, methods and other how-to^ papers, and responses targeted at
a specific published paper^ are not appropriate. Guest Commentaries are
subject to review.^

The length may not exceed 2 printed pages, and the format is^ like that
of a Minireview (see above). Commentaries should be^ submitted via Rapid
Review.^

*Letters to the Editor*

Two types of Letters to the Editor may be submitted. The first^ type
(Comment Letter) is intended for comments on final, typeset^ articles
published in the journal (/not/ on publish-ahead-of-print^ manuscripts)
and must cite published references to support the^ writer's argument.
The second type (New-Data Letter) may report^ new, concise findings that
are not appropriate for publication^ as full-length papers or Notes.^

Letters may be *no more than 500 words long and must be typed^ double
spaced*. Refer to a recently published Letter for correct^ formatting.
Note that authors and affiliations are listed at^ the foot of the
Letter. Provide only the primary affiliation^ for each author.^

All Letters to the Editor must be submitted electronically,^ and the
type of Letter (New Data or Comment) must be selected^ from the
drop-down list in the submission form. For Letters^ commenting on
published articles, the cover letter should state^ the volume and issue
in which the article was published, the^ title of the article, and the
last name of the first author.^ In the Abstract section of the
submission form, put "Not applicable."^ Letters to the Editor do not
have abstracts. Both types of Letter^ must have a title, which must
appear on the manuscript and on^ the submission form. Figures and tables
should be kept to a^ minimum.^

If the Letter is related to a published article, it will be^ sent to the
editor who handled the article in question. If the^ editor believes that
publication is warranted, he will solicit^ a reply from the
corresponding author of the article and make^ a recommendation to the
editor in chief. Final approval for^ publication rests with the editor
in chief.^

New-Data Letters will be assigned to an editor according to^ subject
matter and will be reviewed by that editor and the editor^ in chief.
Final approval for publication rests with the editor^ in chief.^

*Please note that some indexing/abstracting services do not include^
Letters to the Editor in their databases.*^

*Errata*

The Erratum section provides a means of correcting errors that^ occurred
during the writing, typing, editing, or printing (e.g.,^ a misspelling,
a dropped word or line, or mislabeling in a figure)^ of a published
article. Submit Errata via Rapid Review (see^ "How To Submit
Manuscripts," above). In the Abstract section^ of the submission form (a
required field), put "Not Applicable."^ Upload the text of your Erratum
as an MS Word file. Please see^ a recent issue for correct formatting.^

*Authors' Corrections*

The Author's Correction section provides a means of correcting^ errors
of omission (e.g., author names or citations) and errors^ of a
scientific nature that do not alter the overall basic results^ or
conclusions of a published article (e.g., an incorrect unit^ of
measurement or order of magnitude used throughout, contamination^ of one
of numerous cultures, or misidentification of a mutant^ strain, causing
erroneous data for only a portion [noncritical]^ of the study). /Note
that the addition of new data is not permitted/.^

For corrections of a scientific nature or issues involving authorship,^
including contributions and use or ownership of data and/or^ materials,
all disputing parties must agree, in writing, to^ publication of the
Correction. For omission of an author's name,^ letters must be signed by
the authors of the article and the^ author whose name was omitted. The
editor who handled the article^ will be consulted if necessary.^

Submit an Author's Correction via Rapid Review (see "How To^ Submit
Manuscripts," above). In the submission form, select^ Erratum as the
manuscript type; there is no separate selection^ in Rapid Review for
Authors' Corrections, but your Correction^ will be published as such if
appropriate. In the Abstract section^ of the submission form (a required
field), put "Not Applicable."^ Upload the text of your Author's
Correction as an MS Word file.^ Please see a recent issue for correct
formatting. Signed letters^ of agreement must be supplied as
supplemental material (scanned^ PDF files).^

*Retractions*

Retractions are reserved for major errors or breaches of ethics^ that,
for example, may call into question the source of the^ data or the
validity of the results and conclusions of an article.^ Submit
Retractions via Rapid Review (see "How To Submit Manuscripts,"^ above).
In the Abstract section of the submission form (a required^ field), put
"Not Applicable." Upload the text of your Retraction^ as an MS Word
file. Letters of agreement signed by all of the^ authors must be
supplied as supplemental material (scanned PDF^ files). The Retraction
will be assigned to the editor in chief^ of the journal, and the editor
who handled the paper and the^ chairman of the ASM Publication Board
will be consulted. If^ all parties agree to the publication and content
of the Retraction,^ it will be sent to the Journals Department for
publication.^


	   ILLUSTRATIONS AND TABLES

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
*Digital files that are acceptable for production (see below)^ must be
provided for all illustrations on return of the modified^ manuscript.
(On initial submission, the entire paper may be^ submitted in PDF
format.)*^

*We strongly recommend that before returning their modified
manuscripts,^ authors check the acceptability of their digital images
for^ production by running their files through Rapid Inspector,* a^ tool
provided at the following URL:
http://rapidinspector.cadmus.com/RapidInspector/zmw/index.jsp.^ Rapid
Inspector is an easy-to-use Web-based application that^ identifies file
characteristics that may render the image unusable^ for production.^

Illustrations may be continuous-tone images, line drawings,^ or
composites. Color graphics may be submitted, but the cost^ of printing
in color must be borne by the author. Suggestions^ about how to reduce
costs and ensure accurate color reproduction^ are given below.^

The preferred format for tables is MS Word; however, WordPerfect^ and
Acrobat PDF are also acceptable (see the section on tables^ below).^

*Image Manipulation*

Computer-generated images may be processed only minimally. Processing^
(e.g., changing contrast, brightness, or color balance) is acceptable^
only if applied to all parts of the image, as well as to the^ controls,
equally, and descriptions of all such adjustments^ and the tools used
(both hardware and software) must be provided^ in the manuscript.
Unprocessed data and files must be retained^ by the authors and be
provided to the editor on request.^

*Illustrations*

*File types and formats.* As mentioned above, *illustrations may be
supplied as PDF files^ for reviewing purposes only on initial
submission; in fact,^ we recommend this option to minimize file upload
time. At the^ modification stage, production quality digital files must
be^ submitted:* TIFF or EPS files from supported applications or^
PowerPoint files (black and white only). Except for figures^ produced in
PowerPoint, all graphics submitted with modified^ manuscripts must be
bitmap, grayscale, or CMYK (/not/ RGB). Halftone^ images (those with
various densities or shades) must be grayscale,^ /not/ bitmap.^

Color PowerPoint files are /not/ accepted because the application,^
designed for developing on-screen computer presentations, uses^ the RGB
color mode whereas the printing process uses the CMYK^ color mode.
Colors that are represented in a PowerPoint image^ may not be
reproducible on a printing press. Although black-and-white^ Microsoft
PowerPoint files are accepted, we do /not/ recommend^ the use of
PowerPoint. PowerPoint requires users to pay close^ attention to the
fonts used in their images (see the section^ on fonts below). If
instructions for fonts are not followed^ /exactly/, images prepared for
publication are subject to missing^ characters, improperly converted
characters, or shifting/obscuring^ of elements or text in the figure.
*Use of PowerPoint is therefore^ not recommended for either color or
black-and-white illustrations.*^

Acceptable file types and formats for production are given in^ the
charts above. More-detailed instructions for preparing illustrations^
are available at http://art.cadmus.com/da/index.jsp. Please^ review this
information before preparing your files. If you^ require additional
information, please send an e-mail inquiry^ to digitalart@cadmus.com
<mailto:digitalart@cadmus.com>.^

*Minimum resolution.* It is extremely important that a high enough
resolution is used.^ Any imported images must be at the correct
resolution before^ they are placed. Note, however, that the higher the
resolution,^ the larger the file and the longer the upload time.
Publication^ quality will /not/ be improved by using a resolution higher
than^ the minimum. Minimum resolutions are as follows:

    300 dpi for^ grayscale and color^
    600 dpi for lettering^
    1,200 dpi for^ line art^
    600 dpi for combination art (lettering and images)^

^

*Size.* All graphics *MUST be submitted at their intended publication^
size*; that is, the image uploaded should be 100% of its print^
dimensions so that no reduction or enlargement is necessary.^ Resolution
must be at the required level at the submitted size.^ Include only the
significant portion of an illustration. White^ space must be cropped
from the image, and excess space between^ panel labels and the image
must be eliminated.

    Maximum width^ for a 1-column figure: 3Formula inches (ca. 8.4 cm)^
    Maximum width for a 2-column figure: 67/8 inches^ (ca. 17.4 cm)^
    Minimum width for a 2-column figure: 41/4 inches^ (10.8 cm)^
    Maximum height: 9Formula inches (23.0 cm)^

^

*Contrast.* Illustrations must contain sufficient contrast to withstand^
the inevitable loss of contrast and detail inherent in the printing^
process. See also "Color illustrations" below.^

*Labeling and assembly.* All final lettering, labeling, tooling, etc.,
*must* be incorporated^ into the figures. It cannot be added at a later
date. If a figure^ number is included, it *must* appear well outside the
boundaries^ of the image itself. (Numbering may need to be changed at
the^ copyediting stage.) Each figure must be uploaded as a separate^
file, and any multipanel figures must be assembled into one^ file; i.e.,
rather than uploading a separate file for each panel^ in a figure,
assemble all panels in one piece and supply them^ as one file.^

*Fonts.* To avoid font problems, set all type in one of the following^
fonts: Helvetica, Times Roman, European PI, Mathematical PI,^ or Symbol.
All fonts other than these five must be converted^ to paths (or
outlines) in the application with which they were^ created. For proper
font use in PowerPoint images, refer to^ the Cadmus digital art website,
http://art.cadmus.com/da/instructions/ppt_disclaimer.jsp.^

*Compression.* Images created with Macintosh applications may be
compressed^ with Stuffit. Images created with Windows applications may
be^ compressed with WinZip or PKZIP.^

*Color illustrations.* /The cost of printing in color must be borne by
the author./ The^ current color cost per figure may be accessed from the
submission^ form in Rapid Review. For accepted manuscripts, the total
cost^ of the color will be included in the acceptance letter sent^ out
by ASM. Adherence to the following guidelines, in addition^ to the
general ones below, will help to minimize costs and to^ ensure color
reproduction that is as accurate as possible.^

Because of the requirements of print production, color illustrations^
*must* be in the CMYK (cyan, magenta, yellow, black) color space.^ The
"normal" color mode for most computer software is RGB (red,^ green,
blue), which is also the color space of your computer^ monitor. Since
CMYK is a smaller color space (meaning it can^ define fewer colors),
colors often shift when an RGB file is^ converted to CMYK. In
particular, figures showing red or green^ fluorescence and those with a
significant range of colors may^ be difficult or impossible to reproduce
during the printing^ process.^

Color illustrations must be supplied in the CMYK color mode,^ as either
(i) CMYK TIFF images with a resolution of at least^ 300 pixels per inch
(raster files, consisting of pixels) or^ (ii) Illustrator-compatible EPS
files with CMYK color elements^ (vector files, consisting of lines,
fonts, fills, and images).^ See the charts above for a list of supported
applications.^

We cannot accept any Microsoft Office files (PowerPoint, Word,^ Excel)
for color illustrations because they are restricted to^ the RGB color
space.^

*Drawings*

Submit graphs, charts, complicated chemical or mathematical^ formulas,
diagrams, and other drawings as finished products^ not requiring
additional artwork or typesetting. No part of^ the graph or drawing may
be handwritten. /All/ elements, including^ letters, numbers, and
symbols, /must/ be easily readable, and^ both axes of a graph must be
labeled. Keep in mind that the^ journal is published both in print and
online and that the same^ electronic files submitted by the authors are
used to produce^ both.^

When creating line art, please use the following guidelines:^

   1. *All art MUST be submitted at its intended publication size.*^ For
      acceptable dimensions, see "Size" above.^
   2. *Avoid using screens^ (i.e., shading)* in line art. It can be
      difficult^ and time-consuming^ to reproduce these images without
      moir^ patterns. Various^ pattern backgrounds are preferable to
      screens^ as long as the^ patterns are not imported from another
      application.^ If you must^ use images containing screens,
          * Generate the image^ at line screens^ of 85 lines per inch or
            lower.^
          * When applying^ multiple shades^ of gray, differentiate the
            gray^ levels by at^ least 20%.^
          * Never^ use levels of gray below 20% or above 70%^ as they
            will^ fade^ out or become totally black upon scanning^ and
            reduction.^
      ^
   3. Use thick, solid lines that are no finer than 1 point in thickness.^
   4. No type should be smaller than 6 points at the final publication^
      size.^
   5. Avoid layering type directly over shaded or textured^ areas.^
   6. Avoid the use of reversed type (white lettering on^ a black
      background).^
   7. Avoid heavy letters, which tend to close^ up, and unusual
      symbols,^ which the printer may not be able to^ reproduce in the
      legend.^
   8. If colors are used, avoid using similar^ shades of the same color^
      and avoid very light colors.^

^

In figure ordinate and abscissa scales (as well as table column^
headings), *avoid the ambiguous use of numbers with exponents.*^
Usually, it is preferable to use the Systme International^ d'Units
(SI) symbols ( for 10^?6 , m for^ 10^?3 , k for 10^3 , M for 10^6 ,
etc.). A complete listing^ of SI symbols can be found in the
International Union of Pure^ and Applied Chemistry (IUPAC) publication
/Quantities, Units^ and Symbols in Physical Chemistry/ (Blackwell
Science, Oxford,^ United Kingdom, 1993); an abbreviated list is
available at http://www.iupac.org/reports/1993/homann/index.html.^ Thus,
a representation of 20,000 cpm on a figure ordinate is^ to be made by
the number 20 accompanied by the label kcpm.^

When powers of 10 must be used, the journal requires that the^ exponent
power be associated with the number shown. In representing^ 20,000 cells
per ml, the numeral on the ordinate would be "2"^ and the label would be
"10^4 cells per ml" (not "cells per ml^ x 10^?4 "). Likewise, an enzyme
activity of 0.06 U/ml would^ be shown as 6 accompanied by the label
10^?2 U/ml. The^ preferred designation would be 60 mU/ml (milliunits per
milliliter).^

*Presentation of Nucleic Acid Sequences*

Nucleic acid sequences of limited length which are the primary^ subject
of a study may be presented freestyle in the most effective^ format.
Longer nucleic acid sequences must be presented as figures^ in the
following format to conserve space. Print the sequence^ in lines of
approximately 100 to 120 nucleotides in a nonproportional^ (monospace)
font that is easily legible when published with^ a line length of 6
inches (ca. 15.2 cm). If possible, lines^ of nucleic acid sequence
should be further subdivided into blocks^ of 10 or 20 nucleotides by
spaces within the sequence or by^ marks above it. Uppercase and
lowercase letters may be used^ to designate the exon-intron structure,
transcribed regions,^ etc., if the lowercase letters remain legible at a
6-inch (ca.^ 15.2-cm) line length. Number the sequence line by line;
place^ numerals, representing the first base of each line, to the left^
of the lines. *Minimize spacing between lines of sequence, leaving^ room
only for annotation of the sequence.* Annotation may include^ boldface,
underlining, brackets, boxes, etc. Encoded amino acid^ sequences may be
presented, if necessary, immediately above^ or below the first
nucleotide of each codon, by using the single-letter^ amino acid
symbols. Comparisons of multiple nucleic acid sequences^ should conform
as nearly as possible to the same format.^

*Figure Legends*

Legends should provide enough information so that the figure^ is
understandable without frequent reference to the text. However,^
detailed experimental methods must be described in the Materials^ and
Methods section, not in a figure legend. A method that is^ unique to one
of several experiments may be reported in a legend^ only if the
discussion is very brief (one or two sentences).^ Define all symbols
used in the figure and define all abbreviations^ that are not used in
the text.^

*Tables*

Tables that contain artwork, chemical structures, or shading^ must be
submitted as illustrations in an acceptable format at^ the modification
stage. The preferred format for regular tables^ is MS Word; however,
WordPerfect and Acrobat PDF are also acceptable.^ Note that a straight
Excel file is /not/ currently an acceptable^ format. Excel files must be
either embedded in a Word or WordPerfect^ document or converted to PDF
/before/ being uploaded. *If your^ modified manuscript contains PDF
tables, select "for reviewing^ purposes only" at the beginning of the
file upload process.*^

Tables should be formatted as follows. Arrange the data so that^
*columns of like material read down, not across.* The headings^ should
be sufficiently clear so that the meaning of the data^ is understandable
without reference to the text. See the "Abbreviations"^ section (p. 18)
of these Instructions for those that should^ be used in tables.
Explanatory footnotes are acceptable, but^ more extensive table
"legends" are not. Footnotes should not^ include detailed descriptions
of the experiment. Tables must^ include enough information to warrant
table format; those with^ fewer than six pieces of data will be
incorporated into the^ text by the copy editor. Table 1 is an example of
a well-constructed^ table.^

*Cover Photographs and Drawings*

JVI publishes photographs and drawings on the front cover. Invitations^
are issued to authors whose manuscripts are returned for modification^
or whose manuscripts have been accepted for publication in JVI;^
material should be related to the work presented in the manuscript.^
Unsolicited photos will be considered in hard-copy format (two^ copies)
only; if an unsolicited photo is chosen for the cover,^ the author may
be asked to submit digital files. No material^ submitted for
consideration will be returned to the author.^ Authors will be notified
only if their cover art is selected.^ Copyright for the chosen material
must be transferred to ASM.^ A short description of the cover material
will be included at^ the end of the table of contents or the author
index of the^ issue. Technical specifications are available from the
cover^ editor, Daniel DiMaio (e-mail: daniel.dimaio@yale.edu
<mailto:daniel.dimaio@yale.edu>).^


	   NOMENCLATURE

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
ABBREVIATIONS AND CONVENTIONS
<#ABBREVIATIONS_AND_CONVENTIONS>

 
*Chemical and Biochemical Nomenclature*

The recognized authority for the names of chemical compounds^ is
/Chemical Abstracts/ (CAS, Columbus, OH) and its indexes. /The^ Merck
Index/, 14th ed. (Merck & Co., Inc., Whitehouse Station,^ NJ, 2006), is
also an excellent source. For biochemical terminology,^ including
abbreviations and symbols, consult /Biochemical Nomenclature^ and
Related Documents/ (Portland Press, London, United Kingdom,^ 1992),
available at http://www.chem.qmul.ac.uk/iupac/bibliog/white.html.,^ and
the instructions to authors of the /Journal of Biological^ Chemistry/
and the /Archives of Biochemistry and Biophysics/ (first^ issues of each
year).^

Do not express molecular weight in daltons; molecular weight^ is a
unitless ratio. Molecular mass is expressed in daltons.^

For enzymes, use the recommended (trivial) name assigned by^ the
Nomenclature Committee of the International Union of Biochemistry^ (IUB)
as described in /Enzyme Nomenclature/ (Academic Press, Inc.,^ New York,
NY, 1992) and at http://www.chem.qmul.ac.uk/iubmb/enzyme/.^ If a
nonrecommended name is used, place the proper (trivial)^ name in
parentheses at first use in the abstract and text. Use^ the EC number
when one has been assigned, and express enzyme^ activity either in
katals (preferred) or in the older system^ of micromoles per minute.^

For nomenclature of restriction enzymes, DNA methyltransferases,^ homing
endonucleases, and their genes, refer to the article^ by Roberts et al.
(Nucleic Acids Res. *31:* 1805-1812, 2003).^

*Nomenclature of Mice*

For mouse strain and genetic nomenclature, ASM encourages authors^ to
refer to the guidelines set forth by the International Committee^ on
Standardized Genetic Nomenclature for Mice, available on^ the Mouse
Genome Database home page at http://www.informatics.jax.org/^ and in
/Genetic Variants and Strains of the Laboratory Mouse/,^ 3rd ed. (M. F.
Lyon et al., ed., Oxford University Press, Oxford,^ England, 1996).^

*Nomenclature of Viruses*

Names used for viruses should be those approved by the International^
Committee on Taxonomy of Viruses (ICTV) and published in /Virus^
Taxonomy: Eighth Report of the International Committee on Taxonomy^ of
Viruses/ (C. M. Fauquet et al., ed., Elsevier Academic Press,^ San
Diego, CA, 2005). In addition, the recommendations of the^ ICTV
regarding the use of species names should generally be^ followed: when
the entire species is discussed as a taxonomic^ entity, the species
name, like other taxa, is italic and has^ the first letter and any
proper nouns capitalized (e.g., /Tobacco^ mosaic virus/, /Murray Valley
encephalitis virus/). When the behavior^ or manipulation of individual
viruses is discussed, the vernacular^ (e.g., tobacco mosaic virus,
Murray Valley encephalitis virus)^ should be used. If desired, synonyms
may be added parenthetically^ when the name is first mentioned. Approved
generic (or group)^ and family names may also be used.^

*Nomenclature of Bacteria*

Binary names, consisting of a generic name and a specific epithet^
(e.g., /Escherichia coli/), should be used for all bacteria. Names^ of
categories at or above the genus level may be used alone,^ but specific
and subspecific epithets may not. A specific epithet^ must be preceded
by a generic name, written out in full the^ first time it is used in a
paper. Thereafter, the generic name^ should be abbreviated to the
initial capital letter (e.g., /E.^ coli/), provided there can be no
confusion with other genera^ used in the paper. Names of all taxa
(kingdoms, phyla, classes,^ orders, families, genera, species, and
subspecies) are printed^ in italics; strain designations and numbers are
not.^

*Genetic Nomenclature*

To facilitate accurate communication, *it is important that standard^
genetic nomenclature be used whenever possible and that deviations^ or
proposals for new naming systems be endorsed by an appropriate^
authoritative body.* Review and/or publication of submitted manuscripts^
that contain new or nonstandard nomenclature may be delayed^ by the
editor or the Journals Department so that they may be^ reviewed by the
Genetics and Genomics Committee of the ASM Publications^ Board.^

*Before submission of manuscripts, authors may direct questions^ on
genetic nomenclature to the committee's chairman: Maria Costanzo^
(e-mail: maria@genome.stanford.edu <mailto:maria@genome.stanford.edu>).*
Such a consultation should^ be mentioned in the manuscript submission
letter.^

When appropriate for viral genetic systems, use the recommendations^ of
Demerec et al. (Genetics *54:* 61-76, 1966) as a guide.

   1. Phenotype^ designations must be employed when mutant loci have^
      not been^ identified or mapped. They can also be used to identify^
      the^ protein product of a gene, e.g., the OmpA protein. Phenotype^
      designations generally consist of three-letter symbols; these^ are
      /not/ italicized and the first letter of the symbol is
      capitalized.^ It is preferable to use Roman or Arabic numerals
      (instead of^ letters) to identify a series of related phenotypes.
      Thus, a^ series of bacteriocin-tolerant mutants might be
      designated TolI,^ TolII, TolIII, etc., or a series of nucleic acid
      polymerase^ mutants might be designated Pol1, Pol2, Pol3, etc.
      Wild-type^ characteristics can be designated Tol^+ or Pol^+ , and,
      when necessary^ for clarity, negative superscripts (Tol^? Pol^? )
      can^ be used to designate mutant characteristics. Lowercase
      superscript^ letters may be used to further delineate phenotypes
      (e.g., Str^r ^ for streptomycin resistance). Phenotype
      designations should^ be defined.^
   2. Genotype designations are also indicated by three-letter^ locus^
      symbols. These are lowercase italic (e.g., /pol src/). If^
      several^ loci govern related functions, these are distinguished^
      by italicized^ capital letters following the locus symbol.^
   3. Wild-type^ alleles are indicated with a superscript plus (/ara/^+
      ^ /his/^+ ). A^ superscript minus is not used to indicate a
      mutant^ locus; thus,^ one refers to an /ara/ mutant rather than an
      /ara/^? ^ strain.^
   4. The rules for genetic nomenclature of viruses (phages) differ^
      from those of bacteria. As a general rule, the entire description^
      of a virus is italicized, including the designations /am/ or
      /sus/^ (amber suppressible) and /ts/ (temperature sensitive).
      Superscripts^ are employed to indicate hybrid genomes. Genetic
      symbols may^ be one, two, or three letters. For example, a mutant
      strain^ of {lambda} might be designated {lambda} /c/I857 /int/2
      /red/114 /susA/11; this strain^ carries mutations in genes /c/I,
      /int/, and /red/ and a suppressible^ (/sus/) mutation in gene /A/.
      A strain designated {lambda} /imm/^21 /att/^434 ^ would represent
      a hybrid of phage {lambda} which carries the immunity^ (/imm/)
      region of phage 21 and the attachment (/att/) region of^ phage
      434. Host DNA insertions into viruses should be delineated^ by
      square brackets, and the genetic symbols and designations^ for
      such inserted DNA should conform to those employed for the^ host
      genome. Genetic symbols for phage {lambda} can be found in
      reports^ by Echols and Murialdo (Microbiol. Rev. *42:*577-591,
      1978) and^ Szybalski and Szybalski (Gene *7:*217-270, 1979).^

^

*Locus tags.* Locus tags are systematic, unique identifiers that are
assigned^ to each gene in GenBank. All genes mentioned in a manuscript^
should be traceable to their sequences by the reader, and locus^ tags
may be used for this purpose in manuscripts to identify^ uncharacterized
genes. However, since locus tags are not genetic^ names, they should
appear in roman type rather than in italics.^ In addition, authors
should check GenBank to make sure that^ they are using the correct,
up-to-date format for locus tags^ (e.g., uppercase versus lowercase
letters, presence or absence^ of an underscore, etc.). Locus tag formats
vary between different^ organisms and also may be updated for a given
organism, so it^ is important to check GenBank at the time of manuscript
preparation.^

*"Mutant" versus "mutation."* Authors are reminded of the distinction
between a /mutation/ (an^ alteration of the primary sequence of the
genetic material)^ and a /mutant/ (a strain carrying one or more
mutations). One^ may speak about the mapping of a mutation, but one
cannot map^ a mutant. Likewise, a mutant has no genetic locus, only a
phenotype.^

*"Homology" versus "similarity."* For use of terms that describe
relationships between genes,^ consult the articles by Theissen (Nature
*415:*741, 2002) and^ Fitch (Trends Genet. *16:*227-231, 2000).^

"Homology" implies a relationship between genes that share a^ common
evolutionary origin; partial homology is not recognized.^ When sequence
comparisons are discussed, it is more appropriate^ to use the term
"percent sequence similarity" or "percent sequence^ identity," as
appropriate.^


	   ABBREVIATIONS AND CONVENTIONS

Top
<#top> SCOPE
<#SCOPE> EDITORIAL POLICY
<#EDITORIAL_POLICY> HOW TO SUBMIT MANUSCRIPTS
<#HOW_TO_SUBMIT_MANUSCRIPTS> ORGANIZATION AND FORMAT
<#ORGANIZATION_AND_FORMAT> ILLUSTRATIONS AND TABLES
<#ILLUSTRATIONS_AND_TABLES> NOMENCLATURE
<#NOMENCLATURE> ABBREVIATIONS AND CONVENTIONS

 
*Verb Tense*

ASM strongly recommends that for clarity you use the *past* tense^ to
narrate particular events in the past, including the procedures,^
observations, and data of the study that you are reporting.^ Use the
present tense for your own general conclusions, the^ conclusions of
previous researchers, and generally accepted^ facts. Thus, most of the
abstract, Materials and Methods, and^ Results will be in the past tense,
and most of the introduction^ and some of the Discussion will be in the
present tense.^

Be aware that it may be necessary to vary the tense in a single^
sentence. For example, it is correct to say "White (30) demonstrat/ed/^
that XYZ cells /grow/ at pH 6.8," "Figure 2 show/s/ that ABC cells^
fail/ed/ to grow at room temperature," and "Air /was/ removed from^ the
chamber and the mice /died/, which /proves/ that mice /require/^ air."
In reporting statistics and calculations, it is correct^ to say "The
values for the ABC cells /are/ statistically significant,^ indicating
that the drug inhibit/ed/ ... ."^

For an in-depth discussion of tense in scientific writing, see^ p.
191-193 in /How To Write and Publish a Scientific Paper/, 6th^ ed.^

*Abbreviations*

*General.* Abbreviations should be used as an aid to the reader, rather^
than as a convenience to the author, and therefore their *use^ should be
limited*. Abbreviations other than those recommended^ by the IUPAC-IUB
(/Biochemical Nomenclature and Related Documents/,^ 1992) should be used
only when a case can be made for necessity,^ such as in tables and
figures.^

It is often possible to use pronouns or to paraphrase a long^ word after
its first use (e.g., "the drug" or "the substrate").^ Standard chemical
symbols and trivial names or their symbols^ (folate, Ala, Leu, etc.) may
also be used.^

It is strongly recommended that all abbreviations except those^ listed
below be introduced in the first paragraph in Materials^ and Methods.
Alternatively, define each abbreviation and introduce^ it in parentheses
the first time it is used; e.g., "cultures^ were grown in Eagle minimal
essential medium (MEM)." Generally,^ eliminate abbreviations that are
not used at least three times^ in the text (including tables and figure
legends).^

*Not requiring introduction.* In addition to abbreviations for Systme
International^ d'Units (SI) units of measurement, other common units^
(e.g., bp, kb, and Da), and chemical symbols for the elements,^ the
following should be used without definition in the title,^ abstract,
text, figure legends, and tables: DNA (deoxyribonucleic^ acid); cDNA
(complementary DNA); RNA (ribonucleic acid); cRNA^ (complementary RNA);
RNase (ribonuclease); DNase (deoxyribonuclease);^ rRNA (ribosomal RNA);
mRNA (messenger RNA); tRNA (transfer RNA);^ AMP, ADP, ATP, dAMP, ddATP,
GTP, etc. (for the respective 5'^ phosphates of adenosine and other
nucleosides) (add 2'-, 3'-,^ or 5'- when needed for contrast); ATPase,
dGTPase, etc. (adenosine^ triphosphatase, deoxyguanosine triphosphatase,
etc.); NAD (nicotinamide^ adenine dinucleotide); NAD^+ (nicotinamide
adenine dinucleotide,^ oxidized); NADH (nicotinamide adenine
dinucleotide, reduced);^ NADP (nicotinamide adenine dinucleotide
phosphate); NADPH (nicotinamide^ adenine dinucleotide phosphate,
reduced); NADP^+ (nicotinamide^ adenine dinucleotide phosphate,
oxidized); poly(A), poly(dT),^ etc. (polyadenylic acid,
polydeoxythymidylic acid, etc.); oligo(dT),^ etc. (oligodeoxythymidylic
acid, etc.); UV (ultraviolet); PFU^ (plaque-forming units); CFU
(colony-forming units); MIC (minimal^ inhibitory concentration); Tris
[tris(hydroxymethyl)aminomethane];^ DEAE (diethylaminoethyl); EDTA
(ethylenediaminetetraacetic acid);^ EGTA [ethylene
glycol-bis(?-aminoethyl ether)-/N/,/N/,/N/',/N/'-tetraacetic^ acid];
HEPES (/N/-2-hydroxyethylpiperazine-/N/'-2-ethanesulfonic^ acid); PCR
(polymerase chain reaction); and AIDS (acquired immunodeficiency^
syndrome). Abbreviations for cell lines (e.g., HeLa) also need^ not be
defined.^

The following abbreviations should be used without definition^ in tables:

    amt (amount)^
    approx (approximately)^
    avg (average)^
    concn (concentration)^
    diam (diameter)^
    expt (experiment)^
    exptl (experimental)^
    ht (height)^
    mo (month)^
    mol wt (molecular^ weight)^
    no. (number)^
    prepn (preparation)^
    SD (standard^ deviation)^
    SE (standard error)^
    SEM (standard error of the^ mean)^
    sp act (specific activity)^
    sp gr (specific gravity)^
    temp (temperature)^
    tr (trace)^
    vol (volume)^
    vs (versus)^
    wk (week)^
    wt (weight)^
    yr (year)^

^

*Drugs and Pharmaceutical Agents*

Chemical or generic names of drugs should be used; the use of^ trade
names is not permitted. When code names or corporate proprietary^
numbers are to be used, either the chemical structure of the^ compound
or a published literature reference illustrating the^ chemical
structure, if known, must be provided at the first^ occurrence of the
code name or number. For compounds not identified^ by generic
nomenclature, all previous or concurrent identification^ numbers or
appellations should be listed in the manuscript.^

*Reporting Numerical Data*

Standard metric units are used for reporting length, weight,^ and
volume. For these units and for molarity, use the prefixes^ m, , n, and
p for 10^?3 , 10^?6 , 10^?9 ,^ and 10^?12 , respectively. Likewise, use
the prefixes c^ for 10^?2 and k for 10^3 . Avoid compound prefixes such
as^ m or . Use g/ml or g/g in^ place of the ambiguous ppm. Units of
temperature are presented^ as follows: 37C or 324 K.^

When fractions are used to express units such as enzymatic activities,^
it is preferable to use whole units, such as g or min, in the^
denominator instead of fractional or multiple units, such as^ g or 10
min. For example, "pmol/min" is preferable to^ "nmol/10 min," and
"mol/g" is preferable to "nmol/g."^ It is also preferable that an
unambiguous form such as exponential^ notation be used; for example,
"mol g^?1 min^?1 "^ is preferable to "mol/g/min." Always report
numerical^ data in the appropriate SI units.^

For a review of some common errors associated with statistical^ analyses
and reports, plus guidelines on how to avoid them,^ see the article by
Olsen (Infect. Immun. *71:*6689-6692, 2003).^

For a review of basic statistical considerations for virology^
experiments, see the article by Richardson and Overbaugh (J.^ Virol.
*79:*669-676, 2005).^

*Isotopically Labeled Compounds*

For simple molecules, labeling is indicated in the chemical^ formula
(e.g., ^14 CO_2 , ^3 H_2 O, and H_2 ^35 SO_4 ). Brackets are not used^
when the isotopic symbol is attached to the name of a compound^ that in
its natural state does not contain the element (e.g.,^ ^32 S-ATP) or to
a word that is not a specific chemical name (e.g.,^ ^131 I-labeled
protein, ^14 C-amino acids, and ^3 H-ligands).^

For specific chemicals, the symbol for the isotope introduced^ is placed
in square brackets directly preceding the part of^ the name that
describes the labeled entity. Note that configuration^ symbols and
modifiers precede the isotopic symbol. The following^ examples
illustrate correct usage:

    [^14 C]urea^
    L-[/methyl/-^14 C]methionine^
    [2,3-^3 H]serine^
    [{alpha}-^14 C]lysine^
    [{gamma}-^32 P]ATP^
    UDP-[U-^14 C]glucose^
    SV40 [^32 P]DNA^
    fructose 1,6-[1-^32 P]bisphosphate^

^

JVI follows the same conventions for isotopic labeling as the^ /Journal
of Biological Chemistry/, and more-detailed information^ can be found in
the instructions to authors of that journal^ (first issue of each year).^

^


*View this table:*
[in this window] </cgi/content/full/82/1/1/TU1>
[in a new window] </cgi/content-nw/full/82/1/1/TU1>

  	Macintosh

 

*View this table:*
[in this window] </cgi/content/full/82/1/1/TU2>
[in a new window] </cgi/content-nw/full/82/1/1/TU2>

  	Windows

 

*View this table:*
[in this window] </cgi/content/full/82/1/1/T1>
[in a new window] </cgi/content-nw/full/82/1/1/T1>

  	TABLE 1. Distribution of protein and ATPase in fractions of dialyzed
membranes^/a/

 

------------------------------------------------------------------------
Journal of Virology, January 2008, p. 1-19, Vol. 82, No. 1
0022-538X/08/$08.00+0     doi:10.1128/JVI.02322-07
Copyright  2008 </misc/terms.shtml>, American Society for Microbiology
<http://www.asm.org>. All Rights Reserved.




This Article
Right arrow	* *Full Text* (PDF) </cgi/reprint/82/1/1> *
Right arrow	* Alert me when this article is cited
</cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jvi;82/1/1&return_type=article&return_url=http%3A%2F%2Fjvi.asm.org%2Fcgi%2Fcontent%2Ffull%2F82%2F1%2F1>*

Right arrow	* Alert me if a correction is posted
</cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=82/1/1&return_type=article&return_url=http%3A%2F%2Fjvi.asm.org%2Fcgi%2Fcontent%2Ffull%2F82%2F1%2F1>*

Services
Right arrow	* Similar articles in this journal
</cgi/search?qbe=jvi;82/1/1&journalcode=jvi&minscore=4000> *
Right arrow	* Alert me to new issues of the journal
<http://journals.asm.org/cgi/alerts/etoc>*
Right arrow	* Download to citation manager </cgi/citmgr?gca=jvi;82/1/1>*
Right arrow	**Copyright Information
<http://www.journals.asm.org/misc/terms.shtml>**
Right arrow	**Books from ASM Press <http://www.asmpress.org/>**
Right arrow	**MicrobeWorld <http://www.microbeworld.org/>**


------------------------------------------------------------------------
Home </> Help </help/> [Feedback] </cgi/feedback> [For Subscribers]
</subscriptions/> [Archive] </contents-by-date.0.shtml> [Search]
</search.dtl> [Contents] </content/vol82/issue1/index.dtl>
J. Bacteriol. <http://jb.asm.org> 	Mol. Cell. Biol.
<http://mcb.asm.org> 	Microbiol. Mol. Biol. Rev. <http://mmbr.asm.org>

Clin. Vaccine Immunol. <http://cvi.asm.org> 	ALL ASM JOURNALS
<http://journals.asm.org>

